GIST: overview and recent advances in treatment with imatinib mesylate
Clinical Previous     Next

GIST: overview and recent advances in treatment with imatinib mesylate

Anne McTiernan Clinical research associate in bone and soft tissue sarcomas, The Meyerstein Institute of Oncology, The Middlesex Hospital, London

The treatment of advanced and metastatic gastrointestinal stromal tumours (GIST) has been revolutionised by the development of the drug imatinib mesylate (Glivec), one of the first targeted molecular therapies available for the treatment of cancer. However, little has been previously documented about this rare tumour. The aim of this article is to provide an overview of GIST and its treatment, and discuss the nursing management of GIST patients. This is particularly timely given that the National Institute for Clinical Excellence is expected to publish its guidance for the use of Glivec in the treatment of unresectable and/or metastatic GISTs this September.

Cancer Nursing Practice. 3, 6,28-32. doi: 10.7748/cnp2004.07.3.6.28.c7573

You need a subscription to read the full article